Nabriva Therapeutics Announces Pricing of Public Offering of Ordinary Shares of Approximately $80 Million
September 19 2017 - 8:53PM
Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing
of its underwritten public offering of 9,411,765 ordinary shares at
a public offering price of $8.50 per share. In addition, Nabriva
Therapeutics has granted the underwriters an option for a period of
30 days to purchase up to an additional 1,411,764 ordinary shares
at the public offering price, less the underwriting discounts and
commissions. All of the ordinary shares in the offering are to be
sold by Nabriva Therapeutics.
The offering is expected to close on or about September 22,
2017, subject to customary closing conditions. Morgan Stanley and
BofA Merrill Lynch are acting as joint book-running managers and
SunTrust Robinson Humphrey, Needham & Company and Wedbush
PacGrow are acting as co-managers for the offering.
The public offering is being made pursuant to a shelf
registration statement, including a prospectus, on Form S-3 that
was filed by Nabriva Therapeutics with the Securities and Exchange
Commission (“SEC”) and was declared effective on August 10, 2017. A
final prospectus supplement relating to and describing the terms of
the offering will be filed with the SEC and will be available on
the SEC’s website at www.sec.gov. The offering is being made only
by means of a prospectus and related prospectus supplement, copies
of which may be obtained by contacting Morgan Stanley, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014, or BofA Merrill Lynch, 200 North College Street, 3rd Floor,
Charlotte, NC 28255-0001, Attention: Prospectus Department, e-mail:
dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy Nabriva Therapeutics’ ordinary
shares, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Offers will be
made only by means of a prospectus supplement and the accompanying
prospectus, forming a part of the registration statement.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged
in the research and development of new medicines to treat serious
bacterial infections, with a focus on the pleuromutilin class of
antibiotics.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, including but not
limited to statements about prospective financings and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “likely,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: market and
other financing conditions, the uncertainties inherent in the
initiation and conduct of clinical trials, availability and timing
of data from clinical trials, whether results of early clinical
trials or trials in different disease indications will be
indicative of the results of ongoing or future trials,
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals, the availability or
commercial potential of product candidates including lefamulin for
use as a first-line empiric monotherapy for the treatment of
moderate to severe CABP, the sufficiency of cash resources and need
for additional financing and such other important factors as are
set forth under the caption "Risk Factors" in Nabriva Therapeutics’
annual and quarterly reports on file with the U.S. Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent Nabriva Therapeutics’
views as of the date of this release. Nabriva Therapeutics
anticipates that subsequent events and developments will cause its
views to change. However, while Nabriva Therapeutics may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Nabriva Therapeutics’ views as of any date subsequent
to the date of this release.
Contact:
INVESTORS
Dave Garrett
Nabriva Therapeutics plc
david.garrett@nabriva.com
610-816-6657
MEDIA
Katie Engleman
Pure Communications
katie@purecommunications.com
910-509-3977
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024